Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Morgan Kruse"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 4, Pp 867-876 (2017)
In the 2015/16 influenza season, the Canadian National Advisory Committee on Immunization (NACI) recommended vaccination with quadrivalent inactivated influenza vaccine (QIV) for infants aged 6–23 months and trivalent inactivated influenza vaccines
Externí odkaz:
https://doaj.org/article/4ecf33f225b145baa353648f5c6e19c6
Publikováno v:
Journal of Osteoporosis, Vol 2015 (2015)
Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PM
Externí odkaz:
https://doaj.org/article/2c819bd5149945ddbd854ee449e187e9
Autor:
Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller, Francesco Lo-Coco, Ashutosh Pathak
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134587 (2015)
The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate
Externí odkaz:
https://doaj.org/article/92f15341f1bd41c6b64db8552990d58c
Autor:
Michelle Vu, Amy M Duhig, Abhishek Tibrewal, Chelsey M Campbell, Abhishek Gaur, Carmela Salomon, Ankita Gupta, Morgan Kruse, Sharief Taraman
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:378-390
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95c0cf46cbbbd66238048483381a3f83
https://doi.org/10.18553/jmcp.2023.29.4.378
https://doi.org/10.18553/jmcp.2023.29.4.378
Autor:
Francesco Lo-Coco, Monique Martin, Morgan Kruse, Martin S. Tallman, Gisoo Barnes, Rebecca Wildner, U Udo Mueller, Boxiong Tang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:771-777
This study estimated the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment.A Markov cohort model was developed with 3 states: stable disease (duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf6ef4f0c017cb2b317c25625b138d8
https://doi.org/10.1016/j.clml.2015.07.634
https://doi.org/10.1016/j.clml.2015.07.634
Autor:
John P. Caloyeras, Daria B. Crittenden, Claire E O'Hanlon, Richard Barron, Anju Parthan, Yawen Jiang, Morgan Kruse, Shannon Cartier, Björn Stollenwerk
Publikováno v:
Clinical therapeutics. 39(7)
Purpose The goal of this study was to assess and compare the potential clinical and economic value of emerging bone-forming agents using the only currently available agent, teriparatide, as a reference case in patients at high, near-term (imminent, 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e4384959b7fa93cf1e14d7176b4916
https://pubmed.ncbi.nlm.nih.gov/28629610
https://pubmed.ncbi.nlm.nih.gov/28629610
Autor:
Morgan Kruse, Anju Parthan, Hema N. Viswanathan, Nicole Yurgin, Douglas C.A. Taylor, Joice Huang
Publikováno v:
Applied Health Economics and Health Policy. 11:485-497
In the US, 26 % of women aged ≥65 years, and over 50 % of women aged ≥85 years are affected with postmenopausal osteoporosis (PMO). Each year, the total direct health care costs are estimated to be $US12–18 billion. The cost effectiveness of de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e1fd4c16694b2d6b2edccd319d553a2
https://doi.org/10.1007/s40258-013-0047-8
https://doi.org/10.1007/s40258-013-0047-8
Autor:
Monique Martin, Rebecca Wildner, Francesco Lo-Coco, Udo Mueller, Gisoo Barnes, Ashutosh K. Pathak, Morgan Kruse
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134587 (2015)
PLoS ONE
PLoS ONE
The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdaf4d141c0375f87809c9b93874caa4
http://hdl.handle.net/2108/160449
http://hdl.handle.net/2108/160449
Publikováno v:
Postgraduate medicine. 125(2)
The objective of this study was to compare the clinical benefit across adjuvant therapies for cancer treatment, including adjuvant imatinib, and to quantify the results using the number-needed-to-treat (NNT) approach.We reviewed studies meeting the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4cc5d910ceac79aa75ab6cf299633a8
https://pubmed.ncbi.nlm.nih.gov/23816774
https://pubmed.ncbi.nlm.nih.gov/23816774
Autor:
Tom Kouroukis, Donna Lawrence, Morgan Kruse, Cristina Trambitas, Matthew C. Cheung, Darrell White
Publikováno v:
Blood. 122:1735-1735
Introduction The effectiveness of bortezomib for induction treatment prior to ASCT in multiple myeloma (MM) patients has been demonstrated in a number of randomized, open-label phase III trials, including the IFM 2005-01 trial (Harousseau et al., J C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a942d7bf7edab8938d943c26fdab96fa
https://doi.org/10.1182/blood.v122.21.1735.1735
https://doi.org/10.1182/blood.v122.21.1735.1735